A Phase III Randomized Study of Intravenous Cisplatin and Cyclophosphamide versus Intravenous Cisplatin and Taxol Versus High Dose Intravenous Carboplatin followed by Intravenous Taxol and Intraperitoneal Cisplatin in Patients with Optimal Stage III Epithelial Ovarian Carcinoma - Intergroup

Closed

Phase

Published

Abbreviated Title

A Phase III Randomized Study of Intravenous Cisplatin and Cyclophosphamide versus Intravenous Cisplatin and Taxol Versus High Dose Intravenous Carboplatin followed by Intravenous Taxol and…

Activated

12/15/1992

Closed

04/03/1995

Research committees

Gynecologic Cancer

Publication Information Expand/Collapse

2002

Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and Intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: and Intergroup study of the GOG, SWOG, and ECOG

M Markman;BN Bundy;DS Alberts;JM Fowler;DL Clark-Pearson;LF Carson;S Wadler;J Sickel Classic Papers and Current Comments 7(1):92-99

2001

Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small volume stage III ovarian carcinoma: An intergroup stud y of the GOG, SWOG, and ECOG

M Markman;BN Bundy;DS Alberts;JM Fowler;DL Clark-Pearson;LF Carson;S Wadler;J Sickel Journal of Clinical Oncology 19(4):1001-1007

1998

Randomized phase 3 study of intravenous (IV) cisplatin (CIS)/paclitaxel (PAC) versus moderately high dose IV carboplatin (CARB) followed by IV PAC and intraperitoneal (IP) CIS in optimal residual ovarian cancer (OC): An intergroup trial (GOG, SWOG, ECOG).

M Markman;B Bundy;J Benda;D Alberts;S Wadler;J Fowler;D Clark-Pearson;LF Carson Proc of the American Society of Clinical Oncology 17:361a(#1392)